<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00913471</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-07-0452</org_study_id>
    <nct_id>NCT00913471</nct_id>
  </id_info>
  <brief_title>Biomarkers for Pain in Spinal Cord Injury (SCI) Patients</brief_title>
  <acronym>SCI Pain</acronym>
  <official_title>Biomarkers for Pain in Spinal Cord Injury (SCI) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Institute for Rehabilitaion and Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to compare plasma protein profiles for SCI patients with/without&#xD;
      chronic neuropathic pain in order identify biomarker(s) that are associated with this medical&#xD;
      condition. Secondly, the investigators propose to identify a temporal relationship to initial&#xD;
      SCI at which these biomarkers manifest.&#xD;
&#xD;
      Our working hypothesis is that sustained alterations in specific inflammatory molecules are&#xD;
      associated with chronic neuropathic pain following SCI, and that their plasma levels can&#xD;
      serve as biomarkers to identify patients at risk for the development of neuropathic pain.&#xD;
&#xD;
      Additionally the investigators are collecting skin tissue biopsy samples from patients&#xD;
      following acute and chronic spinal cord injury to create vector-free human iPS cells from&#xD;
      fibroblasts by direct delivery of reprogramming proteins.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Anticipated">June 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To identify candidate biomarkers for pain in the chronic SCI samples.</measure>
    <time_frame>two or more years post injury</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To identify the temporal relationship of the development of pain and the manifestation of the biomarkers identified</measure>
    <time_frame>two or more years post injury</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Traumatic Spinal Cord Injury</condition>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Acute-Longitudinal SCI</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic SCI</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.&#xD;
Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.&#xD;
Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy.</description>
    <arm_group_label>Acute-Longitudinal SCI</arm_group_label>
    <arm_group_label>Chronic SCI</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples (120 subjects) and skin tissue biopsy (20 subjects)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Acute and Chronic traumatic spinal cord injury patients and healthy volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        A. Chronic Patients&#xD;
&#xD;
        Inclusion:&#xD;
&#xD;
        1. Two or more years post traumatic SCI with deficit&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          1. &lt; 18 years of age&#xD;
&#xD;
          2. Evidence of brain injury on computed tomography (CT) (SCI patients need to be able to&#xD;
             comply with completing the pain survey)&#xD;
&#xD;
          3. Other medical condition that accounts for chronic pain (i.e. diabetic neuropathy,&#xD;
             renal insufficiency, multiple sclerosis, HIV associated neuropathy, alcohol-related&#xD;
             neuropathy)&#xD;
&#xD;
          4. Temperature &gt; 100.5Â°C&#xD;
&#xD;
          5. History of infection within the last 30 days (i.e. UTI, URI, pressure sore)&#xD;
&#xD;
          6. History of Pulmonary Embolus (PE) or deep vein thrombosis (DVT)&#xD;
&#xD;
          7. Inability to obtain informed consent&#xD;
&#xD;
          8. Psychiatric problems (patients need to be able to complete the pain survey)&#xD;
&#xD;
          9. Diagnosis or treatment of cancer in the last 5 years&#xD;
&#xD;
        B. Longitudinal, Prospective Cohort Patients:&#xD;
&#xD;
        Inclusion:&#xD;
&#xD;
        1. Initial traumatic SCI with deficit&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
        Same as listed above C. Healthy Volunteers Healthy volunteers include gender, age and race&#xD;
        matched volunteers able to provide informed consent who have,&#xD;
&#xD;
          1. No significant medical history (pain free)&#xD;
&#xD;
          2. No recent infections&#xD;
&#xD;
          3. Take no medications&#xD;
&#xD;
          4. Fever free&#xD;
&#xD;
          5. Greater than 18 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgene Hergenroeder, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTHSC-Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hergenroeder GW, Moore AN, Schmitt KM, Redell JB, Dash PK. Identification of autoantibodies to glial fibrillary acidic protein in spinal cord injury patients. Neuroreport. 2016 Jan 20;27(2):90-3. doi: 10.1097/WNR.0000000000000502.</citation>
    <PMID>26629661</PMID>
  </reference>
  <reference>
    <citation>Hergenroeder GW, Redell JB, Choi HA, Schmitt L, Donovan W, Francisco GE, Schmitt K, Moore AN, Dash PK. Increased Levels of Circulating Glial Fibrillary Acidic Protein and Collapsin Response Mediator Protein-2 Autoantibodies in the Acute Stage of Spinal Cord Injury Predict the Subsequent Development of Neuropathic Pain. J Neurotrauma. 2018 Nov 1;35(21):2530-2539. doi: 10.1089/neu.2018.5675. Epub 2018 Jul 5.</citation>
    <PMID>29774780</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Georgene Hergenroeder</investigator_full_name>
    <investigator_title>Associate Professor, Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>Spinal cord injury</keyword>
  <keyword>SCI</keyword>
  <keyword>Neuropathic pain</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

